Deakin University, Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
Deakin University, Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Geelong, Australia.
J Affect Disord. 2021 Jan 15;279:711-721. doi: 10.1016/j.jad.2020.10.031. Epub 2020 Oct 16.
Personality disorder (PD) may affect the efficacy of pharmacological interventions for mood disorders, but the extent to which this occurs is uncertain. We aimed to examine the available published evidence concerning the role of PD in pharmacological treatment outcomes of randomised controlled trials (RCTs) for adults with mood disorders (i.e. depressive and bipolar spectrum disorders).
A systematic search of Cochrane Central Register of Controlled Clinical Trials, PubMed, EMBASE, PsycINFO, CINAHL Complete, and Google Scholar databases was undertaken to identify studies of interest. Data were independently extracted by two reviewers. The Cochrane Risk of Bias tool was used to assess methodological quality and risk of bias. A random effects model was utilised and statistical heterogeneity was assessed using the I statistic. This systematic review was registered with PROSPERO (CRD42018089279) and the protocol is published.
The search yielded 11,640 studies. Subsequent to removing duplicates, 9657 studies were screened at title and abstract stage and 1456 were assessed at full-text stage. Eighteen studies met criteria for inclusion in this review. Meta-analysis did not reveal a significant difference between groups for treatment outcome (standardised mean difference 0.22 [-0.09, 0.54]; I: 69%, p=0.17) and remission (risk ratio 0.84 [0.64, 1.11]; I: 51%, p=0.22).
This review was limited by lack of studies on bipolar disorder.
PD comorbidity does not appear to affect treatment efficacy of pharmacological interventions for adults with mood disorders.
人格障碍(PD)可能会影响心境障碍药物干预的疗效,但这种影响的程度尚不确定。我们旨在检查现有关于人格障碍在心境障碍(即抑郁和双相谱系障碍)成人药物治疗结果的随机对照试验(RCT)中作用的已发表证据。
系统检索 Cochrane 对照临床试验中心注册库、PubMed、EMBASE、PsycINFO、CINAHL Complete 和 Google Scholar 数据库,以确定相关研究。由两名评审员独立提取数据。使用 Cochrane 偏倚风险工具评估方法学质量和偏倚风险。采用随机效应模型,使用 I 统计量评估统计异质性。本系统评价已在 PROSPERO(CRD42018089279)注册,并已发表方案。
检索结果产生了 11640 项研究。在去除重复项后,对 9657 项研究进行了标题和摘要筛选,对 1456 项研究进行了全文筛选。有 18 项研究符合纳入本综述的标准。Meta 分析显示,治疗结果(标准化均数差 0.22[-0.09, 0.54];I:69%,p=0.17)和缓解(风险比 0.84[0.64, 1.11];I:51%,p=0.22)两组间无显著差异。
本综述受限于双相障碍研究的缺乏。
PD 共病似乎不会影响心境障碍成人药物干预的治疗效果。